{"mainPropery":{"diseaseId":3045,"diseaseName":"Neuronal ceroid lipofuscinosis 2","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/3045/neuronal-ceroid-lipofuscinosis-2","synonyms":["CLN2","Jansky-Bielschowsky disease","CLN2 disease, late infantile (subtype)","CLN2 disease, juvenile (subtype)"],"synonyms-with-source":[{"name":"CLN2"},{"name":"Jansky-Bielschowsky disease"},{"name":"CLN2 disease, late infantile (subtype)","source":"GeneReviews"},{"name":"CLN2 disease, juvenile (subtype)","source":"GeneReviews"}],"identifiers":[{"identifierType":"OMIM","identifierId":"204500"},{"identifierType":"ORPHANET","identifierId":"228349"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"},{"diseaseTypeId":33,"diseaseTypeName":"RDCRN"}],"organizations":[{"resourceID":315,"resourceName":"Batten Disease Support and Research Association","abbreviation":"BDSRA","address1":"2780 Airport Drive, Suite 342","address2":"","address3":"","address4":"","address5":"","city":"Columbus","state":"OH","zip":"43219","country":"United States","phone":"","tty":"","tollFree":"1-800-448-4570","fax":"1-866-648-8718","email":"https://bdsra.org/contact-us/","url":"https://bdsra.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/204500' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=CLN2%5Btiab%5D%20AND%20Neuronal%20ceroid%20lipofuscinosis%5Btiab%5D&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Neuronal ceroid lipofuscinosis 2. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='https://clinicaltrials.gov/ct2/results?term=%22Neuronal+ceroid+lipofuscinosis+2%22&Search=Search' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Neuronal ceroid lipofuscinosis 2. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='https://ghr.nlm.nih.gov/condition/cln2-disease' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Neuronal ceroid lipofuscinosis 2. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":137,"resourceId":315,"resourceName":"Batten Disease Support and Research Association","descriptionText":"The&nbsp;Batten Disease Support and Research Association has a list of&nbsp;<a href='http://bdsra.org/programs-services/centers-of-excellence/' target='_blank'>Batten Disease Centers of Excellence</a>. These centers have&nbsp;a team of professionals who are knowledgeable about, and have experience treating, all forms of Batten disease.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C1876161/' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/001613.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1530,"resourceId":2161,"resourceName":"National Institute of Neurological Disorders and Stroke (NINDS)","descriptionText":"The <a href='https://www.ninds.nih.gov/Disorders/All-Disorders/Batten-Disease-Information-Page' target='_blank'>National Institute of Neurological Disorders and Stroke</a> (NINDS) collects and disseminates research information related to neurological disorders. Click on the link to view information on&nbsp;this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/1178391-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1532,"resourceId":2163,"resourceName":"Social Security Administration","descriptionText":"The <a href='https://secure.ssa.gov/apps10/poms.nsf/lnx/0423022435' target='_blank'>Social Security Administration</a> has included this condition in their Compassionate Allowances Initiative. This initiative speeds up the processing of disability claims for applicants with certain medical conditions that cause severe disability. More information about <a href=\"http://www.ssa.gov/compassionateallowances/index.htm\" target=\"_blank\">Compassionate Allowances</a> and <a href=\"https://www.ssa.gov/benefits/disability/\" target=\"_blank\">applying for Social Security disability</a> is available online.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228349' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=ncl' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1539,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/ResearchTrials_Search_Simple.php?lng=EN&LnkId=17766&Typ=Pat&RchTyp=Rch' target='_blank'>Orphanet</a> lists European clinical trials, research studies, and patient registries enrolling people with this condition.&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:204500' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Neuronal ceroid lipofuscinosis 2. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Neuronal ceroid lipofuscinosis 2:<br />\r\n<a href='https://www.urmc.rochester.edu/neurology/batten-disease-center/research/research-clinical-trials.aspx' target='_blank'>Batten Disease Registry</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":2269,"questionText":"What is neuronal ceroid lipofuscinosis 2?","answerText":"<strong>Neuronal ceroid lipofuscinosis 2 (CLN2)</strong>&nbsp;is a type of&nbsp;<a href=\"https://rarediseases.info.nih.gov/diseases/10739/neuronal-ceroid-lipofuscinosis\" target=\"_blank\">neuronal ceroid lipofuscinosis</a>&nbsp;(NCL),&nbsp;a group of severe diseases that affect the nervous system. Symptoms of the CLN2 generally develop between ages two and four years, although later onset cases have been reported. Children with CLN2 may experience speech delay, seizures that do not respond to medications, loss of muscle coordination (ataxia), muscle twitches (myoclonus), loss of vision, <a href=\"http://www.parentcenterhub.org/repository/ei-overview/#delay\" target=\"_blank\">developmental delay</a>, and intellectual disability. Symptoms of CLN2 worsen as the child gets older (progressive).[9561][9562][14237] <br />\r\n<br />\r\nCLN2 is caused by changes (pathogenic variations) in the <a href=\"http://ghr.nlm.nih.gov/gene/TPP1\" target=\"_blank\"><em>TPP1</em></a> gene and is inherited in an&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner.[9572][14237]&nbsp;<span style=\"font-size: 12pt;\">Although there is no medication that can currently cure CLN2, in the Spring of 2017 both the United States Food and Drug Administration (FDA) and the European Commission approved the use of c<span style=\"font-size: 12pt;\">erliponase alfa&nbsp;</span><span style=\"font-size: 12pt;\"></span><span style=\"font-size: 12pt;\">(brand name:&nbsp;<a class=\"external-link1 confirmation\" href=\"http://brineura.com/\" target=\"_blank\">Brineura</a>)</span>&nbsp;for children with CLN2. In clinical studies, cerliponase alfa was shown&nbsp;to slow down the progression of the disease.[14236] In addition, other medications and&nbsp;</span>therapies can help relieve some of the symptoms of CLN2.[9561][9562][14237]<br />\r\n<br />\r\n<em>Please note</em>: Batten disease originally referred specifically to the juvenile and most common form of NCL, now known as&nbsp;<a href=\"https://rarediseases.info.nih.gov/diseases/5897/neuronal-ceroid-lipofuscinosis-3\" target=\"_blank\">CLN3</a>. However, the term Batten disease is increasingly used to describe all forms of NCL. All types of NCL also belong to a larger group of diseases known as&nbsp;<a href=\"https://rarediseases.org/rare-diseases/lysosomal-storage-disorders/\" target=\"_blank\">lysosomal storage disorders</a>.[9561]","dateModified":"2018-01-09T00:00:00"},"basicQuestions":[],"references":[],"relatedDiseases":[{"relatedDiseaseId":10739,"relatedDiseaseName":"Neuronal ceroid lipofuscinosis","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":9402,"phenoTypeName":"Abnormal nervous system electrophysiology","percentRanges":"-"},{"phenoTypeId":8720,"phenoTypeName":"Ataxia","percentRanges":"-"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":13447,"phenoTypeName":"Cerebral atrophy","percentRanges":"-"},{"phenoTypeId":14508,"phenoTypeName":"Curvilinear intracellular accumulation of autofluorescent lipopigment storage material","percentRanges":"-"},{"phenoTypeId":14142,"phenoTypeName":"Delayed speech and language development","percentRanges":"-"},{"phenoTypeId":5154,"phenoTypeName":"Developmental regression","percentRanges":"-"},{"phenoTypeId":13584,"phenoTypeName":"Increased extraneuronal autofluorescent lipopigment","percentRanges":"-"},{"phenoTypeId":13707,"phenoTypeName":"Increased neuronal autofluorescent lipopigment","percentRanges":"-"},{"phenoTypeId":10639,"phenoTypeName":"Myoclonus","percentRanges":"-"},{"phenoTypeId":5641,"phenoTypeName":"Progressive visual loss","percentRanges":"-"},{"phenoTypeId":5653,"phenoTypeName":"Retinal degeneration","percentRanges":"-"},{"phenoTypeId":8719,"phenoTypeName":"Seizure","percentRanges":"-"},{"phenoTypeId":5656,"phenoTypeName":"Undetectable electroretinogram","percentRanges":"-"}],"medicalProducts":[{"productId":672,"genericName":"Cerliponase alfa","tradeName":"Brineura","tradeLink":"http://brineura.com/","manufacturer":"","sponsor":"BioMarin Pharmaceutical, Inc.","indication":"To slow the progression of loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/brineura","medlinePlusLink":""}],"EncodedName":"Neuronal_ceroid_lipofuscinosis_2"}